Bonnie S. Glisson
544 works · 28,834 citations · h-index 82
Top works
- Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.
- Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
- Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
- Outcome of Salvage Total Laryngectomy Following Organ Preservation Therapy
- Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225
- Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.
- Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
- Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
- DNA topoisomerase II: A primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- Proliferation dependence of topoisomerase II-mediated drug action
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity.
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- Phase I Trial of Oral Green Tea Extract in Adult Patients With Solid Tumors
- Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.